



Janssen's DARZALEX Faspro has been approved by the FDA for adult patients with high-risk smoldering multiple myeloma

(FDA, Approval)



FDA approved Johnson & Johnson's CAPLYTA as an adjunctive therapy with antidepressants for the treatment of major depressive disorder in adults

(FDA, Approval)



FDA approves UCB's KYGEVVI as the first and only treatment for adults and children with thymidine kinase 2 deficiency (TK2d)

(FDA, Approval)



FDA issues CRL to Biohaven for its VYGLXIA NDA for the treatment of spinocerebellar ataxia

(FDA, CRL)





Vera Therapeutics submits BLA to the FDA under the accelerated approval program for ATACICEPT to treat adults with IgA nephropathy

(FDA, BLA)



FDA grants Orphan Drug Designation to Leukogene Therapeutics' M2T-CD33 (LTI-214) for the treatment of acute myeloid leukemia

(FDA, Orphan Drug)



Evotec and Sandoz sign major deal that could pay Evotec in excess of US \$650 million and royalties for up to 10 biosimilar molecules

(Acquisition)

